




Summary

In one aspect, there is provided a compound of formula (I) wherein



5 including any stereochemically isomeric form thereof, wherein



10 X¹, X², X³ and X⁴ are selected from X¹ is CH, X² is CH, X³ is CH and X⁴ is CH;
or X¹ is N, X² is CH, X³ is CH and X⁴ is CH,
or X¹ is CH, X² is N, X³ is CH and X⁴ is CH,
or X¹ is N, X² is CH, X³ is CH and X⁴ is N,
or X¹ is N, X² is N, X³ is CH and X⁴ is CH, and
or X¹ is CH, X² is N, X³ is N and X⁴ is CH,
wherein each CH is optionally substituted with halo,
C₁₋₄alkyl or C₁₋₄alkyloxy;

Y¹ and Y² are each independently selected from CH, CF and N;

20 R¹ is CH₃ or CH₂CH₃;

R² is hydrogen, halo or C₁₋₄alkyl;

R¹² is C₁₋₂alkyl;

R¹³ and R¹⁴ are each independently selected from C₁₋₆alkyl;

R³ is halo;

R⁴ is C₁₋₆alkyl; C₃₋₆cycloalkyl; di(C₁₋₄alkyl)amino, pyrrolidinyl, Heteroaryl¹; C₁₋₄alkyl substituted with Heteroaryl¹; phenyl; phenyl substituted with 1, 2 or 3 substituents each individually selected from halo, hydroxy, cyano, C₁₋₄alkyl, polyhaloC₁₋₄alkyl, and C₁₋₄alkyloxy; Heteroaryl¹; C₁₋₄alkyl substituted with Heteroaryl¹;

R⁶ is C₂₋₆alkenyl substituted with one or two substituents selected from C₁₋₆alkyl, -(CO)-OR⁷ or -(CO)-NR⁸R⁹; or

-NR⁹-(CO)-Heterocycle wherein said Heterocycle is substituted with one or two substituents each independently selected from halo, hydroxy or C₁₋₄alkyloxy; or

C₃₋₆cycloalkyl or Heterocycle, wherein said C₃₋₆cycloalkyl and Heterocycle is substituted with one or two substituents each independently selected from

C₁₋₆alkyl;

C₁₋₆alkyl substituted with one, two or three substituents each independently selected from halo, hydroxy, hydroxycarbonyl, aminocarbonyl,

C₃₋₆cycloalkyl, C₃₋₆cycloalkyl substituted with one or two substituents

each independently selected from C₁₋₄alkyl, halo, hydroxycarbonyl, and

C₁₋₄alkyl substituted with hydroxycarbonyl;

C₃₋₆alkenyl;

C₃₋₆alkenyl substituted with one or two substituents selected from C₁₋₆alkyl, hydroxy, -(CO)-OR⁷ or -(CO)-NR⁸R⁹;

hydroxy;

cyano;

-(CO)-O-R⁷;

-(CO)-NR¹⁰R¹¹;

-(CO)-NR⁹-SO₂-R⁸;

-(CO)-NR⁹-(CO)-SO₂-R⁸;

-O-(CO)-NR¹⁰R¹¹;

-NR⁸R⁹;

-NR⁹-(CO)-C₁₋₄alkyl;

-NR⁹-(CO)-C₃₋₆cycloalkyl;

-NR⁹-(CO)-O-R⁸;

-NR⁹-(CO)-NR⁹-R⁸;

-NR⁹-SO₂-R⁸;

-SO₂-R⁸;

-SO₂-NR¹⁰R¹¹; or

-SO₂-NR⁹-(CO)-R⁸;

Heteroaryl²;

wherein

R⁷ is hydrogen, or C₁₋₄alkyl;

R⁸ is C₁₋₄alkyl, polyhaloC₁₋₄alkyl, or C₃₋₆cycloalkyl;
each R⁹ is independently selected from hydrogen or C₁₋₄alkyl;
R¹⁰ and R¹¹ are each independently selected from hydrogen; CN; C₁₋₄alkyl;
C₃₋₆alkenyl; polyhaloC₁₋₄alkyl; C₃₋₆cycloalkyl; C₃₋₆cycloalkyl
5 substituted with C₁₋₄alkyl; or C₁₋₄alkyl substituted with hydroxy or
cyano;

Heterocycle is azetidiny, pyrrolodiny, piperidiny, or homopiperidiny;

Heteroaryl¹ is thienyl, pyridiny or pyrimidiny, wherein each Heteroaryl¹ is optionally
substituted with one or two substituents each independently selected from C₁₋₄alkyl,
10 halo, amino, and aminocarbonyl;

Heteroaryl² is pyrrolyl, pyrazolyl or thiazolyl; wherein each Heteroaryl² is optionally
substituted with one or two substituents each independently selected from C₁₋₄alkyl,
halo, -(CO)-OR⁷ or -(CO)-NR⁸R⁹;

or a pharmaceutically acceptable acid addition salt thereof.

15 In another aspect, there is provided a pharmaceutical composition comprising a pharmaceutically
acceptable carrier and a therapeutically active amount of a compound as defined herein.

20 In another aspect, there is provided a process for preparing a pharmaceutical composition as
defined herein wherein a therapeutically active amount of a compound as defined herein is
intimately mixed with a pharmaceutically acceptable carrier.


In another aspect, there is provided a compound as defined herein for use as a medicine.

25 In another aspect, there is provided a compound as defined herein, or a pharmaceutical
composition as defined herein, for use in the treatment of a respiratory syncytial virus infection.



30 In another aspect, there is provided use of a compound as defined herein, or a pharmaceutical
composition as defined herein, in the manufacture of a medicament for the treatment of a
respiratory syncytial virus infection.

Claims

1. A compound of formula (I) wherein



including any stereochemically isomeric form thereof, wherein



X¹, X², X³ and X⁴ are selected from X¹ is CH, X² is CH, X³ is CH and X⁴ is CH;
 or X¹ is N, X² is CH, X³ is CH and X⁴ is CH,
 or X¹ is CH, X² is N, X³ is CH and X⁴ is CH,
 or X¹ is N, X² is CH, X³ is CH and X⁴ is N,
 or X¹ is N, X² is N, X³ is CH and X⁴ is CH, and
 or X¹ is CH, X² is N, X³ is N and X⁴ is CH,
 wherein each CH is optionally substituted with halo,
 C₁₋₄alkyl or C₁₋₄alkyloxy;

Y¹ and Y² are each independently selected from CH, CF and N;

R¹ is CH₃ or CH₂CH₃;

R² is hydrogen, halo or C₁₋₄alkyl;

R¹² is C₁₋₂alkyl;

R¹³ and R¹⁴ are each independently selected from C₁₋₆alkyl;

R³ is halo;

R⁴ is C₁₋₆alkyl; C₃₋₆cycloalkyl; di(C₁₋₄alkyl)amino, pyrrolidinyl, Heteroaryl¹; C₁₋₄alkyl substituted with Heteroaryl¹; phenyl; phenyl substituted with 1, 2 or 3 substituents each individually selected from halo, hydroxy, cyano, C₁₋₄alkyl, polyhaloC₁₋₄alkyl, and C₁₋₄alkyloxy; Heteroaryl¹; C₁₋₄alkyl substituted with Heteroaryl¹;

R⁶ is C₂₋₆alkenyl substituted with one or two substituents selected from C₁₋₆alkyl, -(CO)-OR⁷ or -(CO)-NR⁸R⁹; or

-NR⁹-(CO)-Heterocycle wherein said Heterocycle is substituted with one or two substituents each independently selected from halo, hydroxy or C₁₋₄alkyloxy; or

C₃₋₆cycloalkyl or Heterocycle, wherein said C₃₋₆cycloalkyl and Heterocycle is substituted with one or two substituents each independently selected from

C₁₋₆alkyl;

C₁₋₆alkyl substituted with one, two or three substituents each independently selected from halo, hydroxy, hydroxycarbonyl, aminocarbonyl,

C₃₋₆cycloalkyl, C₃₋₆cycloalkyl substituted with one or two substituents each independently selected from C₁₋₄alkyl, halo, hydroxycarbonyl, and

C₁₋₄alkyl substituted with hydroxycarbonyl;

C₃₋₆alkenyl;

C₃₋₆alkenyl substituted with one or two substituents selected from C₁₋₆alkyl, hydroxy, -(CO)-OR⁷ or -(CO)-NR⁸R⁹;

hydroxy;

cyano;

-(CO)-O-R⁷;

-(CO)-NR¹⁰R¹¹;

-(CO)-NR⁹-SO₂-R⁸;

-(CO)-NR⁹-(CO)-SO₂-R⁸;

-O-(CO)-NR¹⁰R¹¹;

-NR⁸R⁹;

-NR⁹-(CO)-C₁₋₄alkyl;

-NR⁹-(CO)-C₃₋₆cycloalkyl;

-NR⁹-(CO)-O-R⁸;

-NR⁹-(CO)-NR⁹-R⁸;

-NR⁹-SO₂-R⁸;

-SO₂-R⁸;

-SO₂-NR¹⁰R¹¹; or

-SO₂-NR⁹-(CO)-R⁸;

Heteroaryl²;

wherein

R⁷ is hydrogen, or C₁₋₄alkyl;

R⁸ is C₁₋₄alkyl, polyhaloC₁₋₄alkyl, or C₃₋₆cycloalkyl;
each R⁹ is independently selected from hydrogen or C₁₋₄alkyl;
R¹⁰ and R¹¹ are each independently selected from hydrogen; CN; C₁₋₄alkyl;
C₃₋₆alkenyl; polyhaloC₁₋₄alkyl; C₃₋₆cycloalkyl; C₃₋₆cycloalkyl
substituted with C₁₋₄alkyl; or C₁₋₄alkyl substituted with hydroxy or
cyano;

Heterocycle is azetidiny, pyrrolodiny, piperidiny, or homopiperidiny;

Heteroaryl¹ is thienyl, pyridiny or pyrimidiny, wherein each Heteroaryl¹ is optionally
substituted with one or two substituents each independently selected from C₁₋₄alkyl,
halo, amino, and aminocarbonyl;

Heteroaryl² is pyrrolyl, pyrazolyl or thiazolyl; wherein each Heteroaryl² is optionally
substituted with one or two substituents each independently selected from C₁₋₄alkyl,
halo, -(CO)-OR⁷ or -(CO)-NR⁸R⁹;

or a pharmaceutically acceptable acid addition salt thereof.

2. The compound as claimed in claim 1 wherein radical A is of formula (a-1).
3. The compound as claimed in claim 1 wherein radical A is of formula (a-2).
4. The compound as claimed in claim 1 wherein X¹ is CH, X² is N, X³ is N and X⁴ is CH.
5. The compound as claimed in claim 1 wherein X¹ is N, X² is N, X³ is CH and X⁴ is CH.
6. The compound as claimed in any one of claims 1 to 5 wherein R⁵ is of formula (b-1)
wherein Y¹ and Y² are CH.
7. The compound as claimed in any one of claims 1 to 6 wherein R³ is fluoro.
8. The compound as claimed in any one of claims 1 to 7 wherein R⁴ is C₃₋₆cycloalkyl.
9. The compound as claimed in any one of claims 1 to 8 wherein R⁶ is C₃₋₆cycloalkyl or
pyrrolidinyl, wherein said C₃₋₆cycloalkyl or pyrrolidinyl are substituted with one or two
substituents each independently selected from -(CO)-O-R⁷ or -(CO)-NR¹⁰R¹¹.
10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a
therapeutically active amount of a compound as claimed in any of claims 1 to 9.
11. The pharmaceutical composition according to claim 10, which further comprises another
antiviral agent.

12. The pharmaceutical composition according to claim 11, wherein the other antiviral agent is a RSV inhibiting compound.
- 5 13. A process for preparing a pharmaceutical composition as claimed in any one of claims 10 to 12 wherein a therapeutically active amount of a compound as claimed in any one of claims 1 to 9 is intimately mixed with a pharmaceutically acceptable carrier.
14. A compound as claimed in any one of claims 1 to 9 for use as a medicine.
- 10 15. A compound as claimed in any one of claims 1 to 9, or a pharmaceutical composition as claimed in any one of claims 10 to 12, for use in the treatment of a respiratory syncytial virus infection.
- 15 16. Use of a compound as claimed in any one of claims 1 to 9, or a pharmaceutical composition as claimed in any one of claims 10 to 12, in the manufacture of a medicament for the treatment of a respiratory syncytial virus infection.